Open Access. Powered by Scholars. Published by Universities.®
- Keyword
-
- Research &;; Experimental (6)
- Research & Experimental (3)
- Biochemistry & Molecular Biology;; Cell Biology;; Medicine (2)
- General & Internal (2)
- A-BETA;; MICROGLIAL ACTIVATION;; ENDOCANNABINOID SYSTEM;; TGCRND8 MICE;; TANGLES;; PROTEIN;; CANNABINOIDS;; INFLAMMATION;; BRAIN;; NEUROINFLAMMATION;; Biochemistry & Molecular Biology;; Cell Biology;; Medicine (1)
-
- AGGRESSIVE YOUTH TRAAY;; TREATMENT RECOMMENDATIONS;; TRENDS;; Pediatrics;; Pharmacology & Pharmacy;; Psychiatry (1)
- ATTENTION-DEFICIT/HYPERACTIVITY DISORDER;; DEFICIT HYPERACTIVITY;; DISORDER;; PREFRONTAL CORTEX;; D1 GENE;; ASSOCIATION;; CHILDHOOD;; CHILDREN;; LINKAGE;; BRAIN;; DRD1;; Psychology (1)
- Actin;; Endothelial cells;; Inflammation;; Tissue injury;; Vitamin D binding;; protein;; FULMINANT HEPATIC-NECROSIS;; ACUTE LIVER-FAILURE;; ORGAN DYSFUNCTION;; SCAVENGER SYSTEM;; GLOBULIN;; RECRUITMENT;; CHEMOTAXIS;; TOXICITY;; INJURY;; MICE;; Immunology (1)
- Adolescence;; Diagnosis;; Premorbid;; Prodrome;; Prospective;; Psychosis;; Social adjustment;; 1ST EPISODE PSYCHOSIS;; ULTRA-HIGH-RISK;; PREMORBID ADJUSTMENT;; SCHIZOAFFECTIVE DISORDER;; NEGATIVE SYMPTOMS;; ADULT SCHIZOPHRENIA;; PRODROMAL SYMPTOMS;; BIPOLAR DISORDER;; OBSTETRIC COMPLICATIONS;; INTERRATER RELIABILITY;; Psychiatry (1)
- Adolescents;; Adverse effects;; Antipsychotics;; Children;; Pharmacovigilance;; Registry (1)
- Adolescents;; antipsychotics;; attention deficit-hyperactivity disorder;; children;; combination;; disruptive behaviour disorders;; paediatric;; polypharmacy;; 2ND-GENERATION ANTIPSYCHOTICS;; PSYCHOTROPIC MEDICATION;; ATYPICAL;; ANTIPSYCHOTICS;; PSYCHIATRIC-PATIENTS;; TARDIVE-DYSKINESIA;; CLINICAL-PRACTICE;; NATIONAL TRENDS;; ADVERSE EVENTS;; SCHIZOPHRENIA;; PATTERNS (1)
- Adult;; Antirheumatic Agents/adverse effects/ therapeutic use;; Cyclophosphamide/adverse effects/ therapeutic use;; Dose-Response Relationship (1)
- Aging;; cognition;; development;; diffusion tensor imaging;; executive;; functioning;; white matter;; CINGULATE CORTEX;; CORPUS-CALLOSUM;; LIFE-SPAN;; DIFFUSION;; BRAIN;; INTEGRITY;; ADOLESCENTS;; UNCERTAINTY;; CHOICE;; Neurosciences;; Psychiatry (1)
- All-cause discontinuation;; cohort study;; first-generation antipsychotics;; hospitalization;; long-acting injectable;; risperidone;; schizophrenia (1)
- Alzheimer's disease;; antipsychotics;; psychosis;; tau;; behavioral;; disturbance;; agitation;; POSITRON-EMISSION-TOMOGRAPHY;; PLACEBO-CONTROLLED-TRIAL;; CEREBROSPINAL-FLUID TAU;; BEHAVIORAL DISTURBANCES;; NEUROPSYCHIATRIC;; SYMPTOMS;; DOUBLE-BLIND;; RISK-FACTORS;; ANTIPSYCHOTIC MEDICATIONS;; NEUROFIBRILLARY TANGLES;; ATYPICAL ANTIPSYCHOTICS;; Clinical Neurology;; Psychiatry (1)
- Alzheimer's disease;; long-term potentiation;; neurodegeneration;; protein;; synthesis;; signaling;; translation;; EUKARYOTIC ELONGATION-FACTOR-2 KINASE;; ALZHEIMERS-DISEASE;; TRANSLATIONAL;; REGULATION;; MEMORY DEFICITS;; ENERGY SENSOR;; LIFE-SPAN;; PHOSPHORYLATION;; MECHANISMS;; PATHWAY;; HOMEOSTASIS;; Neurosciences (1)
- Anti-psychotic agent;; Aripiprazole once-monthly;; Hospitalization;; Long-acting injectable;; Schizophrenia (1)
- Antipsychotic;; pharmacogenetics;; polymorphism;; psychosis;; CLOZAPINE-INDUCED AGRANULOCYTOSIS;; DTNBP1 DYSBINDIN GENE;; INDUCED;; WEIGHT-GAIN;; HIGH-RISK HAPLOTYPE;; RECEPTOR GENE;; NEGATIVE SYMPTOMS;; DEFICIT SYNDROME;; 5-HT2A RECEPTOR;; ATYPICAL ANTIPSYCHOTICS;; FUNCTIONAL;; DISABILITY;; Psychiatry (1)
- Antipsychotics;; Quetiapine;; Aripiprazole;; Psychosis;; Schizophrenia;; Children;; Adolescents;; Randomised trial;; Benefits;; Harms;; SCHIZOPHRENIA-SPECTRUM DISORDERS;; EARLY-ONSET SCHIZOPHRENIA;; QUALITY-OF-LIFE;; FULLY CONDITIONAL SPECIFICATION;; PLACEBO-CONTROLLED;; TRIAL;; OPEN-LABEL;; 2ND-GENERATION ANTIPSYCHOTICS;; MULTIPLE IMPUTATION;; NATIONAL TRENDS;; 1ST-EPISODE SCHIZOPHRENIA;; Psychiatry (1)
- Antipsychotics;; adherence;; depot;; long-acting injection;; meta-analysis;; relapse;; schizophrenia;; treatment discontinuation;; SCHIZOAFFECTIVE DISORDER;; FLUPHENAZINE DECANOATE;; MAINTENANCE TREATMENT;; CLINICAL-TRIAL;; TERM TREATMENT;; DOUBLE-BLIND;; OPEN-LABEL;; RISPERIDONE;; THERAPY;; OLANZAPINE;; Psychiatry (1)
- Autoantibodies;; behavior;; FDG-microPET;; N-methyl-D-aspartate receptor;; stereological neuron count;; RESONANCE-IMAGING FINDINGS;; GLUCOSE-METABOLISM;; MICE;; AUTOANTIBODIES;; ABNORMALITIES;; MECHANISMS;; BEHAVIOR;; IMMUNITY;; MEMORY;; PET;; Endocrinology & Metabolism;; Hematology;; Neurosciences (1)
- BIPOLAR-DISORDER (1)
- Biological;; Behavioral Sciences (1)
- Biomarkers;; motor skills;; robotics;; sensory motor performance;; stroke;; MODIFIED RANKIN SCALE;; ASSISTED THERAPY;; OUTCOME MEASURE;; TRIALS;; ARCHIVE;; RELIABILITY;; REHABILITATION;; QSAR;; PATIENT;; Clinical Neurology;; Peripheral Vascular Disease (1)
- Bipolar disorders;; Early recognition;; Early intervention;; Cognitive-behavioural psychotherapy;; Intervention study;; Randomised;; controlled trial;; OF-THE-LITERATURE;; ULTRA-HIGH RISK;; SPECTRUM DISORDER;; EARLY;; INTERVENTION;; RATING-SCALE;; EARLY-ONSET;; PSYCHOSIS;; THERAPY;; PREVALENCE;; PEOPLE;; Medicine (1)
- Bone morphogenetic proteins;; lung neoplasms;; cell proliferation;; cell;; survival;; RNA interference;; preclinical drug evaluation;; microRNAs;; TRANSFORMING-GROWTH-FACTOR;; PREDICT SURVIVAL;; MESSENGER-RNA;; TUMOR-GROWTH;; EXPRESSION;; MICRORNA;; ACTIVATION;; ADENOCARCINOMA;; DORSOMORPHIN;; CARCINOMAS;; Oncology (1)
- Brain development (1)
- Brain networks;; corticobasal degeneration;; differential diagnosis;; FDG;; PET;; glucose metabolism;; PROGRESSIVE SUPRANUCLEAR PALSY;; DIFFERENTIAL-DIAGNOSIS;; PARKINSONIAN-SYNDROMES;; ALZHEIMERS-DISEASE;; ACCURACY;; PATTERNS;; ATROPHY;; ONSET;; Clinical Neurology;; Neurosciences (1)
- CD4(+) T-CELLS;; DENDRITIC CELLS;; INTERLEUKIN-1 FAMILY;; SKIN;; INFLAMMATION;; DISEASE SEVERITY;; IN-VIVO;; EXPRESSION;; TOLERANCE;; IL-36;; SUPPRESSION;; Biochemistry & Molecular Biology;; Cell Biology;; Medicine (1)
- CELL;; GLOMERULONEPHRITIS;; ERYTHEMATOSUS;; INFLAMMATION;; DISEASE;; Rheumatology (1)
Articles 1 - 30 of 72
Full-Text Articles in Medicine and Health Sciences
Circulating Biomarkers For Detection Of Ovarian Cancer And Predicting Cancer Outcomes, I. Shapira, M. Oswald, J. Lovecchio, H. Khalili, A. Menzin, Jill Whyte, L. Dos Santos, S. Liang, T. Bhuiya, M. Keogh, C. Mason, K. Sultan, D. Budman, P. K. Gregersen, A. T. Lee
Circulating Biomarkers For Detection Of Ovarian Cancer And Predicting Cancer Outcomes, I. Shapira, M. Oswald, J. Lovecchio, H. Khalili, A. Menzin, Jill Whyte, L. Dos Santos, S. Liang, T. Bhuiya, M. Keogh, C. Mason, K. Sultan, D. Budman, P. K. Gregersen, A. T. Lee
Journal Articles
Background: Securing a diagnosis of ovarian cancer and establishing means to predict outcomes to therapeutics remain formidable clinical challenges. Early diagnosis is particularly important since survival rates are markedly improved if tumour is detected early. Methods: Comprehensive miRNA profiles were generated on presurgical plasma samples from 42 women with confirmed serous epithelial ovarian cancer, 36 women diagnosed with a benign neoplasm, and 23 comparably age-matched women with no known pelvic mass. Results: Twenty-two miRNAs were differentially expressed between healthy controls and the ovarian cancer group (P
Brain Region-Specific Alterations In The Gene Expression Of Cytokines, Immune Cell Markers And Cholinergic System Components During Peripheral Endotoxin-Induced Inflammation, H. A. Silverman, M. Dancho, A. Regnier-Golanov, M. Nasim, M. Ochani, P. S. Olofsson, M. Ahmed, E. J. Miller, S. S. Chavan, E. Golanov, C. Metz, K. J. Tracey, V. A. Pavlov
Brain Region-Specific Alterations In The Gene Expression Of Cytokines, Immune Cell Markers And Cholinergic System Components During Peripheral Endotoxin-Induced Inflammation, H. A. Silverman, M. Dancho, A. Regnier-Golanov, M. Nasim, M. Ochani, P. S. Olofsson, M. Ahmed, E. J. Miller, S. S. Chavan, E. Golanov, C. Metz, K. J. Tracey, V. A. Pavlov
Journal Articles
Inflammatory conditions characterized by excessive peripheral immune responses are associated with diverse alterations in brain function, and brain-derived neural pathways regulate peripheral inflammation. Important aspects of this bidirectional peripheral immune - brain communication, including the impact of peripheral inflammation on brain region-specific cytokine responses, and brain cholinergic signaling (which plays a role in controlling peripheral cytokine levels) remain unclear. To provide insight, we studied gene expression of cytokines, immune cell markers and brain cholinergic system components in the cortex, cerebellum, brainstem, hippocampus, hypothalamus, striatum, and thalamus in mice following an intraperitoneal lipopolysaccharide injection. Endotoxemia was accompanied by elevated serum levels …
Gene-Based Therapies In Parkinson's Disease, P. J. Allen, A. Feigin
Gene-Based Therapies In Parkinson's Disease, P. J. Allen, A. Feigin
Journal Articles
Parkinson's disease (PD) is a progressive neurological disorder characterized primarily by the degeneration of nigrostriatal dopaminergic neurons and diminution of the neurotransmitter dopamine. Though dopamine replacement therapies such as levodopa can improve the symptoms of PD, the benefits may be overshadowed by side effects and the onset of symptoms not responsive to dopaminergic treatments (e.g., autonomic symptoms, gait and balance problems, and cognitive impairment). Furthermore, no therapies have proven to slow the neurodegenerative process. Novel approaches to address these difficult problems, and others, are being sought. Over the last decade, several innovative gene therapies for PD have entered human clinical …
A Disease-Specific Metabolic Brain Network Associated With Corticobasal Degeneration, M. Niethammer, C. C. Tang, A. Feigin, P. J. Allen, L. Heinen, S. Hellwig, F. Amtage, E. Hanspal, J. P. Vonsattel, D. Eidelberg, +3 Addtional Authors
A Disease-Specific Metabolic Brain Network Associated With Corticobasal Degeneration, M. Niethammer, C. C. Tang, A. Feigin, P. J. Allen, L. Heinen, S. Hellwig, F. Amtage, E. Hanspal, J. P. Vonsattel, D. Eidelberg, +3 Addtional Authors
Journal Articles
Corticobasal degeneration is an uncommon parkinsonian variant condition that is diagnosed mainly on clinical examination. To facilitate the differential diagnosis of this disorder, we used metabolic brain imaging to characterize a specific network that can be used to discriminate corticobasal degeneration from other atypical parkinsonian syndromes. Ten non-demented patients (eight females/two males; age 73.9 +/- 5.7 years) underwent metabolic brain imaging with 18 F-fluorodeoxyglucose positron emission tomography for atypical parkinsonism. These individuals were diagnosed clinically with probable corticobasal degeneration. This diagnosis was confirmed in the three subjects who additionally underwent post-mortem examination. Ten age-matched healthy subjects (five females/five males; age …
Brain Network Markers Of Abnormal Cerebral Glucose Metabolism And Blood Flow In Parkinson's Disease, S. C. Peng, D. Eidelberg, Y. L. Ma
Brain Network Markers Of Abnormal Cerebral Glucose Metabolism And Blood Flow In Parkinson's Disease, S. C. Peng, D. Eidelberg, Y. L. Ma
Journal Articles
Neuroimaging of cerebral glucose metabolism and blood flow is ideally suited to assay widely-distributed brain circuits as a result of local molecular events and behavioral modulation in the central nervous system. With the progress in novel analytical methodology, this endeavor has succeeded in unraveling the mechanisms underlying a wide spectrum of neurodegenerative diseases. In particular, statistical brain mapping studies have made significant strides in describing the pathophysiology of Parkinson's disease (PD) and related disorders by providing signature biomarkers to determine the systemic abnormalities in brain function and evaluate disease progression, therapeutic responses, and clinical correlates in patients. In this article, …
Characterization Of Disease-Related Covariance Topographies With Ssmpca Toolbox: Effects Of Spatial Normalization And Pet Scanners, S. C. Peng, Y. L. Ma, P. G. Spetsieris, P. Mattis, Andrew Feigin, V. Dhawan, D. Eidelberg
Characterization Of Disease-Related Covariance Topographies With Ssmpca Toolbox: Effects Of Spatial Normalization And Pet Scanners, S. C. Peng, Y. L. Ma, P. G. Spetsieris, P. Mattis, Andrew Feigin, V. Dhawan, D. Eidelberg
Journal Articles
To generate imaging biomarkers from disease-specific brain networks, we have implemented a general toolbox to rapidly perform scaled subprofile modeling (SSM) based on principal component analysis (PCA) on brain images of patients and normals. This SSMPCA toolbox can define spatial covariance patterns whose expression in individual subjects can discriminate patients from controls or predict behavioral measures. The technique may depend on differences in spatial normalization algorithms and brain imaging systems. We have evaluated the reproducibility of characteristic metabolic patterns generated by SSMPCA in patients with Parkinson's disease (PD). We used [F-18]fluorodeoxyglucose PET scans from patients with PD and normal controls. …
Radiation Absorbed Dose To The Basal Ganglia From Dopamine Transporter Radioligand F-18-Fpcit, W. Robeson, V. Dhawan, Y. L. Ma, D. Bjelke, C. Margouleff, T. Chaly, D. Eidelberg
Radiation Absorbed Dose To The Basal Ganglia From Dopamine Transporter Radioligand F-18-Fpcit, W. Robeson, V. Dhawan, Y. L. Ma, D. Bjelke, C. Margouleff, T. Chaly, D. Eidelberg
Journal Articles
Our previous dosimetry studies have demonstrated that for dopaminergic radiotracers, F-18-FDOPA and F-18-FPCIT, the urinary bladder is the critical organ. As these tracers accumulate in the basal ganglia (BG) with high affinity and long residence times, radiation dose to the BG may become significant, especially in normal control subjects. We have performed dynamic PET measurements using F-18-FPCIT in 16 normal adult subjects to determine if in fact the BG, although not a whole organ, but a well-defined substructure, receives the highest dose. Regions of interest were drawn over left and right BG structures. Resultant time-activity curves were generated and used …
Consistent Abnormalities In Metabolic Network Activity In Idiopathic Rapid Eye Movement Sleep Behaviour Disorder, P. Wu, H. Yu, S. C. Peng, Y. Dauvilliers, J. Wang, J. J. Ge, H. W. Zhang, D. Eidelberg, Y. L. Ma, C. T. Zuo
Consistent Abnormalities In Metabolic Network Activity In Idiopathic Rapid Eye Movement Sleep Behaviour Disorder, P. Wu, H. Yu, S. C. Peng, Y. Dauvilliers, J. Wang, J. J. Ge, H. W. Zhang, D. Eidelberg, Y. L. Ma, C. T. Zuo
Journal Articles
Rapid eye movement sleep behaviour disorder has been evaluated using Parkinson's disease-related metabolic network. It is unknown whether this disorder is itself associated with a unique metabolic network. F-18-fluorodeoxyglucose positron emission tomography was performed in 21 patients (age 65.0 +/- 5.6 years) with idiopathic rapid eye movement sleep behaviour disorder and 21 age/gender-matched healthy control subjects (age 62.5 +/- 7.5 years) to identify a disease-related pattern and examine its evolution in 21 hemi-parkinsonian patients (age 62.6 +/- 5.0 years) and 16 moderate parkinsonian patients (age 56.9 +/- 12.2 years). We identified a rapid eye movement sleep behaviour disorder-related metabolic network …
Thalamocortical Connectivity Correlates With Phenotypic Variability In Dystonia, An Vo, W. Sako, M. Niethammer, M. Carbon, S. B. Bressman, A. M. Ulug, D. Eidelberg
Thalamocortical Connectivity Correlates With Phenotypic Variability In Dystonia, An Vo, W. Sako, M. Niethammer, M. Carbon, S. B. Bressman, A. M. Ulug, D. Eidelberg
Journal Articles
Dystonia is a brain disorder characterized by abnormal involuntary movements without defining neuropathological changes. The disease is often inherited as an autosomal-dominant trait with incomplete penetrance. Individuals with dystonia, whether inherited or sporadic, exhibit striking phenotypic variability, with marked differences in the somatic distribution and severity of clinical manifestations. In the current study, we used magnetic resonance diffusion tensor imaging to identify microstructural changes associated with specific limb manifestations. Functional MRI was used to localize specific limb regions within the somatosensory cortex. Microstructural integrity was preserved when assessed in subrolandic white matter regions somatotopically related to the clinically involved limbs, …
Regional Brain Metabolism In A Murine Systemic Lupus Erythematosus Model, An Vo, B. T. Volpe, C. C. Tang, W. K. Schiffer, C. Kowal, P. T. Huerta, A. M. Ulug, S. L. Dewey, D. Eidelberg, B. Diamond
Regional Brain Metabolism In A Murine Systemic Lupus Erythematosus Model, An Vo, B. T. Volpe, C. C. Tang, W. K. Schiffer, C. Kowal, P. T. Huerta, A. M. Ulug, S. L. Dewey, D. Eidelberg, B. Diamond
Journal Articles
Systemic lupus erythematosus (SLE) is characterized by multiorgan inflammation, neuropsychiatric disorders (NPSLE), and antinuclear antibodies. We previously identified a subset of anti-DNA antibodies (DNRAb) cross-reactive with the N-methyl-D-aspartate receptor, present in 30% to 40% of patients, able to enhance excitatory post-synaptic potentials and trigger neuronal apoptosis. DNRAb + mice exhibit memory impairment or altered fear response, depending on whether the antibody penetrates the hippocampus or amygdala. Here, we used 18F-fluorodeoxyglucose (FDG) microPET to plot changes in brain metabolism after regional blood-brain barrier (BBB) breach. In DNRAb + mice, metabolism declined at the site of BBB breach in the first 2 …
Optimal Treatment Of Alzheimer's Disease Psychosis: Challenges And Solutions, Jeremy Koppel, Blaine Greenwald
Optimal Treatment Of Alzheimer's Disease Psychosis: Challenges And Solutions, Jeremy Koppel, Blaine Greenwald
Journal Articles
Psychotic symptoms emerging in the context of neurodegeneration as a consequence of Alzheimer's disease was recognized and documented by Alois Alzheimer himself in his description of the first reported case of the disease. Over a quarter of a century ago, in the context of attempting to develop prognostic markers of disease progression, psychosis was identified as an independent predictor of a more-rapid cognitive decline. This finding has been subsequently well replicated, rendering psychotic symptoms an important area of exploration in clinical history taking - above and beyond treatment necessity - as their presence has prognostic significance. Further, there is now …
Hospitalization Rates In Patients Switched From Oral Anti-Psychotics To Aripiprazole Once-Monthly: Final Efficacy Analysis, John Kane, C. Zhao, B. R. Johnson, R. A. Baker, A. Eramo, R. D. Mcquade, A. R. Duca, R. Sanchez, T. Peters-Strickland
Hospitalization Rates In Patients Switched From Oral Anti-Psychotics To Aripiprazole Once-Monthly: Final Efficacy Analysis, John Kane, C. Zhao, B. R. Johnson, R. A. Baker, A. Eramo, R. D. Mcquade, A. R. Duca, R. Sanchez, T. Peters-Strickland
Journal Articles
Abstract Objective: To compare hospitalization rates in patients with schizophrenia treated prospectively with aripiprazole once-monthly 400 mg (AOM 400; an extended-release injectable suspension) vs the same patients' retrospective rates with their prior oral anti-psychotic therapy. Research design and methods: Multi-center, open-label, mirror-image, naturalistic study in a community setting in North America. Patients who required a change in treatment and/or would benefit from long-acting injectable anti-psychotic therapy were treated prospectively for 6 months with AOM 400. Retrospective data on hospitalization rates were obtained. Clinical trial registration: ClinicalTrials.gov: NCT01432444. Main outcome measures: The proportion of patients with >/=1 psychiatric inpatient hospitalization with …
Long-Acting Injectable Vs Oral Antipsychotics For Relapse Prevention In Schizophrenia: A Meta-Analysis Of Randomized Trials, Taishiro Kishimoto, A. Robenzadeh, C. Leucht, S. Leucht, K. Watanabe, M. Mimura, M. Borenstein, John Kane, Christoph Correll
Long-Acting Injectable Vs Oral Antipsychotics For Relapse Prevention In Schizophrenia: A Meta-Analysis Of Randomized Trials, Taishiro Kishimoto, A. Robenzadeh, C. Leucht, S. Leucht, K. Watanabe, M. Mimura, M. Borenstein, John Kane, Christoph Correll
Journal Articles
Background: While long-acting injectable antipsychotics (LAIs) are hoped to reduce high relapse rates in schizophrenia, recent randomized controlled trials (RCTs) challenged the benefits of LAIs over oral antipsychotics (OAPs). Methods: Systematic review/meta-analysis of RCTs that lasted = 6 months comparing LAIs and OAPs. Primary outcome was study-defined relapse at the longest time point; secondary outcomes included relapse at 3, 6, 12, 18, and 24 months, all-cause discontinuation, discontinuation due to adverse events, drug inefficacy (ie, relapse + discontinuation due to inefficacy), hospitalization, and nonadherence. Results: Across 21 RCTs (n = 5176), LAIs were similar to OAPs for relapse prevention at …
Cb2 Receptor Deficiency Increases Amyloid Pathology And Alters Tau Processing In A Transgenic Mouse Model Of Alzheimer's Disease, Jeremy Koppel, V. Vingtdeux, P. Marambaud, C. D'Abramo, H. Jimenez, M. Stauber, R. Friedman, P. Davies
Cb2 Receptor Deficiency Increases Amyloid Pathology And Alters Tau Processing In A Transgenic Mouse Model Of Alzheimer's Disease, Jeremy Koppel, V. Vingtdeux, P. Marambaud, C. D'Abramo, H. Jimenez, M. Stauber, R. Friedman, P. Davies
Journal Articles
The endocannabinoid CB2 receptor system has been implicated in the neuropathology of Alzheimer's disease (AD). In order to investigate the impact of the CB2 receptor system on AD pathology, a colony of mice with a deleted CB2 receptor gene, CNR2, was established on a transgenic human mutant APP background for pathological comparison with CB2 receptor-sufficient transgenic mice. J20 APP (PDGFB-APPSwInd) mice were bred over two generations with CNR2(-/-) (Cnr2(tm1Dgen)/J) mice to produce a colony of J20 CNR2(+/+) and J20 CNR2(-/-)mice. Seventeen J20 CNR2(+/+) mice (12 females, 5 males) and 16 J20 CNR2(-/-) mice (11 females, 5 males) were killed at …
Positive And Negative Subclinical Symptoms And Mccb Performance In Non-Psychiatric Controls, C. Korponay, G. C. Nitzburg, Anil Malhotra, P. Derosse
Positive And Negative Subclinical Symptoms And Mccb Performance In Non-Psychiatric Controls, C. Korponay, G. C. Nitzburg, Anil Malhotra, P. Derosse
Journal Articles
Considerable data support the phenomenological and temporal continuity between subclinical psychosis and psychotic disorders. In recent years, neurocognitive deficits have increasingly been recognized as a core feature of psychotic illness but there are few data seeking to elucidate the relationship between subclinical psychosis and neurocogntive deficits in non-clinical samples. The goal of the present study was to examine the relationship between subclinical positive and negative symptoms, as measured by the Community Assessment of Psychic Experiences (CAPE) and performance on the MATRICS Consensus Cognitive Battery (MCCB) in a large (n=303) and demographically diverse non-clinical sample. We found that compared to participants …
Does A Glp-1 Receptor Agonist Change Glucose Tolerance In Patients Treated With Antipsychotic Medications? Design Of A Randomised, Double-Blinded, Placebo-Controlled Clinical Trial, J. R. Larsen, L. Vedtofte, J. J. Holst, P. Oturai, A. Kjaer, Christoph Correll, T. Vilsboll, A. Fink-Jensen
Does A Glp-1 Receptor Agonist Change Glucose Tolerance In Patients Treated With Antipsychotic Medications? Design Of A Randomised, Double-Blinded, Placebo-Controlled Clinical Trial, J. R. Larsen, L. Vedtofte, J. J. Holst, P. Oturai, A. Kjaer, Christoph Correll, T. Vilsboll, A. Fink-Jensen
Journal Articles
Background Metabolic disturbances, obesity and life-shortening cardiovascular morbidity are major clinical problems among patients with antipsychotic treatment. Especially two of the most efficacious antipsychotics, clozapine and olanzapine, cause weight gain and metabolic disturbances. Additionally, patients with schizophrenia-spectrum disorders not infrequently consume alcohol. Glucagon-like peptide-1 (GLP-1) has shown to improve glycaemic control and reduce alcohol intake among patients with type 2 diabetes. Objectives To investigate whether the beneficial effects of GLP-1 analogues on glycaemic control and alcohol intake, in patients with type 2 diabetes, can be extended to a population of pre-diabetic psychiatric patients receiving antipsychotic treatment. Methods and analysis Trial …
Molecular Genetic Evidence For Overlap Between General Cognitive Ability And Risk For Schizophrenia: A Report From The Cognitive Genomics Consortium (Cogent), T. Lencz, E. Knowles, G. Davies, S. Guha, D. C. Liewald, J. M. Starr, S. Djurovic, I. Melle, K. Sundet, A. Christoforou, I. Reinvang, S. Mukherjee, P. Derosse, A. Lundervold, V. M. Steen, M. John, T. Espeseth, K. Raikkonen, E. Widen, A. Palotie, J. G. Eriksson, I. Giegling, B. Konte, M. Ikeda, P. Roussos, S. Giakoumaki, K. E. Burdick, A. Payton, W. Ollier, M. Horan, G. Donohoe, D. Morris, A. Corvin, M. Gill, N. Pendleton, N. Iwata, A. Darvasi, P. Bitsios, D. Rujescu, J. Lahti, S. L. Hellard, M. C. Keller, O. A. Andreassen, I. J. Deary, D. C. Glahn, Anil Malhotra
Molecular Genetic Evidence For Overlap Between General Cognitive Ability And Risk For Schizophrenia: A Report From The Cognitive Genomics Consortium (Cogent), T. Lencz, E. Knowles, G. Davies, S. Guha, D. C. Liewald, J. M. Starr, S. Djurovic, I. Melle, K. Sundet, A. Christoforou, I. Reinvang, S. Mukherjee, P. Derosse, A. Lundervold, V. M. Steen, M. John, T. Espeseth, K. Raikkonen, E. Widen, A. Palotie, J. G. Eriksson, I. Giegling, B. Konte, M. Ikeda, P. Roussos, S. Giakoumaki, K. E. Burdick, A. Payton, W. Ollier, M. Horan, G. Donohoe, D. Morris, A. Corvin, M. Gill, N. Pendleton, N. Iwata, A. Darvasi, P. Bitsios, D. Rujescu, J. Lahti, S. L. Hellard, M. C. Keller, O. A. Andreassen, I. J. Deary, D. C. Glahn, Anil Malhotra
Journal Articles
It has long been recognized that generalized deficits in cognitive ability represent a core component of schizophrenia (SCZ), evident before full illness onset and independent of medication. The possibility of genetic overlap between risk for SCZ and cognitive phenotypes has been suggested by the presence of cognitive deficits in first-degree relatives of patients with SCZ; however, until recently, molecular genetic approaches to test this overlap have been lacking. Within the last few years, large-scale genome-wide association studies (GWAS) of SCZ have demonstrated that a substantial proportion of the heritability of the disorder is explained by a polygenic component consisting of …
Alpha 7 Nicotinic Acetylcholine Receptor Signaling Inhibits Inflammasome Activation By Preventing Mitochondrial Dna Release, B. Lu, K. Kwan, Y. A. Levine, P. S. Olofsson, H. Yang, J. H. Li, S. Joshi, H. C. Wang, U. Andersson, S. S. Chavan, K. J. Tracey
Alpha 7 Nicotinic Acetylcholine Receptor Signaling Inhibits Inflammasome Activation By Preventing Mitochondrial Dna Release, B. Lu, K. Kwan, Y. A. Levine, P. S. Olofsson, H. Yang, J. H. Li, S. Joshi, H. C. Wang, U. Andersson, S. S. Chavan, K. J. Tracey
Journal Articles
The mammalian immune system and the nervous system coevolved under the influence of cellular and environmental stress. Cellular stress is associated with changes in immunity and activation of the NACHT, LRR and PYD domains-containing protein 3 (NLRP3) inflammasome, a key component of innate immunity. Here we show that alpha 7 nicotinic acetylcholine receptor (alpha 7 nAchR)-signaling inhibits inflammasome activation and prevents release of mitochondrial DNA, an NLRP3 ligand. Cholinergic receptor agonists or vagus nerve stimulation significantly inhibits inflammasome activation, whereas genetic deletion of alpha 7 nAchR significantly enhances inflammasome activation. Acetylcholine accumulates in macrophage cytoplasm after adenosine triphosphate (ATP) stimulation …
Genes And Schizophrenia: From A Festschrift Seminar Honoring William T. Carpenter Jr, Md, Anil Malhotra
Genes And Schizophrenia: From A Festschrift Seminar Honoring William T. Carpenter Jr, Md, Anil Malhotra
Journal Articles
Recent data have begun to elucidate the genetic architecture of schizophrenia, as well as provide new insights into the relationships of specific genetic factors across diagnostic boundaries, with specific symptom domains, and in the prediction of antipsychotic treatment response. Not surprisingly, work conducted at the Maryland Psychiatric Research Center (MPRC), led by Dr William Carpenter, has helped to guide the thinking behind much of this work, as well as contributed valuable data toward these efforts. In this article, I will briefly summarize some of the major findings emerging from these lines of research and highlight the role of the Dr …
The Relationship Of Neurocognition And Negative Symptoms To Social And Role Functioning Over Time In Individuals At Clinical High Risk In The First Phase Of The North American Prodrome Longitudinal Study, E. C. Meyer, Ricardo Carrion, Barbara Cornblatt, J. Addington, K. S. Cadenhead, T. D. Cannon, T. H. Mcglashan, D. O. Perkins, M. T. Tsuang, L. J. Seidman, +3 Additional Authors
The Relationship Of Neurocognition And Negative Symptoms To Social And Role Functioning Over Time In Individuals At Clinical High Risk In The First Phase Of The North American Prodrome Longitudinal Study, E. C. Meyer, Ricardo Carrion, Barbara Cornblatt, J. Addington, K. S. Cadenhead, T. D. Cannon, T. H. Mcglashan, D. O. Perkins, M. T. Tsuang, L. J. Seidman, +3 Additional Authors
Journal Articles
OBJECTIVES: Impaired social, role, and neurocognitive functioning are preillness characteristics of people who later develop psychosis. In people with schizophrenia, neurocognition and negative symptoms are associated with functional impairment. We examined the relative contributions of neurocognition and symptoms to social and role functioning over time in clinically high-risk (CHR) individuals and determined if negative symptoms mediated the influence of cognition on functioning. METHODS: Social, role, and neurocognitive functioning and positive, negative, and disorganized symptoms were assessed in 167 individuals at CHR for psychosis in the North American Prodrome Longitudinal Study Phase 1 (NAPLS-1), of whom 96 were reassessed at 12 …
The Relationship Between Fasting Serum Glucose And Cerebral Glucose Metabolism In Late-Life Depression And Normal Aging, C. M. Marano, C. I. Workman, C. H. Lyman, E. Kramer, C. R. Hermann, Y. L. Ma, V. Dhawan, T. Chaly, D. Eidelberg, G. S. Smith
The Relationship Between Fasting Serum Glucose And Cerebral Glucose Metabolism In Late-Life Depression And Normal Aging, C. M. Marano, C. I. Workman, C. H. Lyman, E. Kramer, C. R. Hermann, Y. L. Ma, V. Dhawan, T. Chaly, D. Eidelberg, G. S. Smith
Journal Articles
Evidence exists for late-life depression (LLD) as both a prodrome of and risk factor for Alzheimer's disease (AD). The underlying neurobiological mechanisms are poorly understood. Impaired peripheral glucose metabolism may explain the association between depression and AD given the connection between type 2 diabetes mellitus with both depression and AD. Positron emission tomography (PET) measures of cerebral glucose metabolism are sensitive to detecting changes in neural circuitry in LLD and AD. Fasting serum glucose (FSG) in non-diabetic young (YC; n=20) and elderly controls (EC; n=12) and LLD patients (n = 16) was correlated with PET scans of cerebral glucose metabolism …
The Content Of Attenuated Psychotic Symptoms In Those At Clinical High Risk For Psychosis, C. Marshall, E. Denny, K. S. Cadenhead, T. D. Cannon, Barbara Cornblatt, T. H. Mcglashan, D. O. Perkins, L. J. Seidman, M. T. Tsuang, J. Addington, +2 Additional Authors
The Content Of Attenuated Psychotic Symptoms In Those At Clinical High Risk For Psychosis, C. Marshall, E. Denny, K. S. Cadenhead, T. D. Cannon, Barbara Cornblatt, T. H. Mcglashan, D. O. Perkins, L. J. Seidman, M. T. Tsuang, J. Addington, +2 Additional Authors
Journal Articles
Recent research has started to focus on identifying individuals who are at clinical high risk of developing psychosis as a means to try and understand the predictors and mechanisms involved in the progress to a full psychotic episode. The aim of the current study was to provide an initial description and prevalence rates of specific content found within attenuated positive symptoms. The Content of Attenuated Positive Symptoms (CAPS) codebook was used by independent raters to determine the presence of content within a sample of written vignettes. Krippendorff's alpha was used to determine inter-rater reliability. Overall, the majority of items fell …
Bdnf Val66met Polymorphism And Antipsychotic-Induced Tardive Dyskinesia Occurrence And Severity: A Meta-Analysis, I. Miura, Jianping Zhang, M. Nitta, T. Lencz, John Kane, Anil Malhotra, H. Yabe, Christoph Correll
Bdnf Val66met Polymorphism And Antipsychotic-Induced Tardive Dyskinesia Occurrence And Severity: A Meta-Analysis, I. Miura, Jianping Zhang, M. Nitta, T. Lencz, John Kane, Anil Malhotra, H. Yabe, Christoph Correll
Journal Articles
Background: Tardive dyskinesia (TD) is a serious long-term consequence of antipsychotic treatment. Since brain-derived neurotrophic factor (BDNF) has potent neurotrophic activity, genetic alterations in the BDNF gene may affect antipsychotic-induced TD. Methods: Searching PubMed and Web of Science until 05/31/13, we conducted a systematic review and a meta-analysis of the effects of BDNF Val66Met polymorphism on antipsychotic-induced TD. Pooled odds ratio was calculated to assess the effects of BDNF Val66Met polymorphism on TD occurrence. Additionally, pooled standardized mean differences (Hedges'g) were calculated to assess the effects on Abnormal Involuntary Movement Scale (AIMS) total score. Results: Out of 699 potentially eligible …
Excess Of Homozygosity In The Major Histocompatibility Complex In Schizophrenia, S. Mukherjee, S. Guha, M. Ikeda, N. Iwata, Anil Malhotra, I. Pe'er, A. Darvasi, T. Lencz
Excess Of Homozygosity In The Major Histocompatibility Complex In Schizophrenia, S. Mukherjee, S. Guha, M. Ikeda, N. Iwata, Anil Malhotra, I. Pe'er, A. Darvasi, T. Lencz
Journal Articles
Genome-wide association studies (GWAS) in schizophrenia have focused on additive allelic effects to identify disease risk loci. In order to examine potential recessive effects, we applied a novel approach to identify regions of excess homozygosity in an ethnically homogenous cohort: 904 schizophrenia cases and 1640 controls drawn from the Ashkenazi Jewish (AJ) population. Genome-wide examination of runs of homozygosity identified an excess in cases localized to the major histocompatibility complex (MHC). To refine this signal, we used the recently developed GERMLINE algorithm to identify chromosomal segments shared identical-by-descent (IBD) and compared homozygosity at such segments in cases and controls. We …
Matrics Cognitive Consensus Battery (Mccb) Performance In Children, Adolescents, And Young Adults, G. C. Nitzburg, P. Derosse, K. E. Burdick, B. D. Peters, C. B. Gopin, Anil Malhotra
Matrics Cognitive Consensus Battery (Mccb) Performance In Children, Adolescents, And Young Adults, G. C. Nitzburg, P. Derosse, K. E. Burdick, B. D. Peters, C. B. Gopin, Anil Malhotra
Journal Articles
Background: Neurodevelopmental models of schizophrenia suggest that cognitive deficits may be observed during childhood and adolescence, long before the onset of psychotic symptoms. Elucidating the trajectory of normal cognitive development during childhood and adolescence may therefore provide a basis for identifying specific abnormalities related to the development of schizophrenia. The MATRICS Consensus Cognitive Battery (MCCB), which was designed for use in clinical trials targeting cognitive deficits most common in schizophrenia, may provide a mechanism to understand this trajectory. To date, however, there is no performance data for the MCCB in healthy children and adolescents. The present study sought to establish …
Comparative Effectiveness Of Risperidone Long-Acting Injectable Vs First-Generation Antipsychotic Long-Acting Injectables In Schizophrenia: Results From A Nationwide, Retrospective Inception Cohort Study, J. Nielsen, S. O. Jensen, R. B. Friis, J. B. Valentin, Christoph Correll
Comparative Effectiveness Of Risperidone Long-Acting Injectable Vs First-Generation Antipsychotic Long-Acting Injectables In Schizophrenia: Results From A Nationwide, Retrospective Inception Cohort Study, J. Nielsen, S. O. Jensen, R. B. Friis, J. B. Valentin, Christoph Correll
Journal Articles
Objective: To compare in a generalizable sample/setting objective outcomes in patients receiving first-generation antipsychotic long-acting injectables (FGA-LAIs) or risperidone-LAI (RIS-LAI). Methods: Nationwide, retrospective inception cohort study of adults with International Classification of Diseases-10 schizophrenia using Danish registers from 1995 to 2009 comparing outcomes between clinician's/patient's choice treatment with FGA-LAIs or RIS-LAI. Primary outcome was time to psychiatric hospitalization using Cox-regression adjusting for relevant covariates. Secondary outcomes included time to all-cause discontinuation and psychiatric hospitalization in patients without LAI possession gap >28 days, and number of bed-days after psychiatric hospitalization. Results: Among 4532 patients followed for 2700 patient-years, 2078 received RIS-LAI …
Sentia: A Systematic Online Monitoring Registry For Children And Adolescents Treated With Antipsychotics, I. Palanca-Maresca, B. Ruiz-Antoran, G. Centeno-Soto, S. Jimenez-Fernandez, L. Garcia-Murillo, A. Siles, S. Villagra, H. Blasco-Fontecilla, L. Iruela-Cuadrado, Christoph Correll, +2 Additional Authors
Sentia: A Systematic Online Monitoring Registry For Children And Adolescents Treated With Antipsychotics, I. Palanca-Maresca, B. Ruiz-Antoran, G. Centeno-Soto, S. Jimenez-Fernandez, L. Garcia-Murillo, A. Siles, S. Villagra, H. Blasco-Fontecilla, L. Iruela-Cuadrado, Christoph Correll, +2 Additional Authors
Journal Articles
INTRODUCTION: Despite drastic increases in antipsychotic prescribing in youth, data are still limited regarding their safety in this vulnerable population, necessitating additional tools for capturing long-term, real world data. METHODS: We present SENTIA (SafEty of NeurolepTics in Infancy and Adolescence; https://SENTIA.es), an online registry created in 2010 to track antipsychotic adverse effects in Spanish youthsociodemographic, diagnostic and treatment characteristics, past personal medical/psychiatric history, healthy lifestyle habits and treatment adherence. Additionally, efficacy and adverse effect data are recorded including the Children's Global Assessment Scale; Clinical Global Impressions scale for Severity and Improvement, the Safety Monitoring Uniform Report Form, Simpson-Angus Scale, Abnormal …
Quetiapine Versus Aripiprazole In Children And Adolescents With Psychosis - Protocol For The Randomised, Blinded Clinical Tolerability And Efficacy Of Antipsychotics (Tea) Trial, A. K. Pagsberg, P. Jeppesen, D. G. Klauber, K. G. Jensen, D. Ruda, M. Stentebjerg-Olesen, P. Jantzen, S. Rasmussen, Christoph Correll, B. Fagerlund, +19 Additional Authors
Quetiapine Versus Aripiprazole In Children And Adolescents With Psychosis - Protocol For The Randomised, Blinded Clinical Tolerability And Efficacy Of Antipsychotics (Tea) Trial, A. K. Pagsberg, P. Jeppesen, D. G. Klauber, K. G. Jensen, D. Ruda, M. Stentebjerg-Olesen, P. Jantzen, S. Rasmussen, Christoph Correll, B. Fagerlund, +19 Additional Authors
Journal Articles
Background: The evidence for choices between antipsychotics for children and adolescents with schizophrenia and other psychotic disorders is limited. The main objective of the Tolerability and Efficacy of Antipsychotics (TEA) trial is to compare the benefits and harms of quetiapine versus aripiprazole in children and adolescents with psychosis in order to inform rational, effective and safe treatment selections. Methods/Design: The TEA trial is a Danish investigator-initiated, independently funded, multi-centre, randomised, blinded clinical trial. Based on sample size estimation, 112 patients aged 12-17 years with psychosis, antipsychotic-naive or treated for a limited period are, 1:1 randomised to a 12-week, double-blind intervention …
Age-Related Differences In White Matter Tract Microstructure Are Associated With Cognitive Performance From Childhood To Adulthood, B. D. Peters, T. Ikuta, P. Derosse, M. John, K. E. Burdick, P. Gruner, D. M. Prendergast, Philip Szeszko, Anil Malhotra
Age-Related Differences In White Matter Tract Microstructure Are Associated With Cognitive Performance From Childhood To Adulthood, B. D. Peters, T. Ikuta, P. Derosse, M. John, K. E. Burdick, P. Gruner, D. M. Prendergast, Philip Szeszko, Anil Malhotra
Journal Articles
Background: Age-related differences in white matter tract microstructure have been well established across the life span. In the present cross-sectional study, we examined whether these differences are associated with neurocognitive performance from childhood to late adulthood. Methods: Diffusion tensor imaging was performed in 296 healthy subjects aged 8 to 68 years (mean = 29.6, SD = 14.6). The corpus callosum, two projection tracts, and five association tracts were traced using probabilistic tractography. A neurocognitive test battery was used to assess speed of processing, attention, spatial working memory, verbal functioning, visual learning, and executive functioning. Linear mediation models were used to …
Antipsychotic Treatment For Children And Adolescents With Schizophrenia Spectrum Disorders: Protocol For A Network Meta-Analysis Of Randomised Trials, A. K. Pagsberg, S. Tarp, D. Glintborg, A. D. Stenstrom, A. Fink-Jensen, Christoph Correll, R. Christensen
Antipsychotic Treatment For Children And Adolescents With Schizophrenia Spectrum Disorders: Protocol For A Network Meta-Analysis Of Randomised Trials, A. K. Pagsberg, S. Tarp, D. Glintborg, A. D. Stenstrom, A. Fink-Jensen, Christoph Correll, R. Christensen
Journal Articles
Introduction: Antipsychotic treatment in early-onset schizophrenia (EOS) lacks a rich evidence base, and efforts to rank different drugs concerning their efficacy have not proven any particular drug superior. In contrast to the literature regarding adult-onset schizophrenia (AOS), comparative effectiveness studies in children and adolescents are limited in number and size, and only a few meta-analyses based on conventional methodologies have been conducted. Methods and analyses: We will conduct a network meta-analysis of all randomised controlled trials (RCTs) that evaluate antipsychotic therapies for EOS to determine which compounds are efficacious, and to determine the relative efficacy and safety of these treatments …